Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.